Cereno Scientific receives patent approval in Australia for use of drug candidate CS1
Cereno Scientific has received a new granted patent in Australia. The patent broadens the protection for the use of the drug candidate, CS1, in an important market for the company. The granted patent ”Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors” is the second granted patent in Cereno Scientifics first patent family.
“It´s positive that we receive this information, which significantly strengthens the intellectual property rights for CS1 in an important drug market. During the autumn, we have also entered the national phase in just under twenty countries for our third patent family, which will further strengthen the protection for our treatment concept,” says Cereno Scientific's CEO Sten R. Sörensen.
The Australian patent will be valid through 2032, with the possibility of a patent extension of an additional five year maximum.
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on March 7th 2019.